Chloroplasts: Transforming Biopharmaceutical Manufacturing - The primary development model for producing human recombinant proteins in tobacco is based on green tissue (leaf) biomass processing. - Bi


Chloroplasts: Transforming Biopharmaceutical Manufacturing
The primary development model for producing human recombinant proteins in tobacco is based on green tissue (leaf) biomass processing.

BioPharm International

The most cost-effective extraction method is compression sieving or screw press. Plant material is fed into the screw press in a continuous manner, and compression under high pressure ruptures the plant cell walls. The compressed material is moved along a sieve plate, which separates the plant-derived extract from solids. This type of extraction equipment is low-tech and readily available from equipment vendors. Screw press extraction uses natural plant liquids, eliminating the need to pay for additional solvents.

Table 3. Selected Component Composition of Tobacco (Green Tissue)
Clarification Once the target protein has been extracted from tobacco, residual plant solids, bioburden, oils, and other extraneous matter must be removed. Typically, the two methods employed are centrifugation and filtration. Centrifugation generally requires a larger capital investment than filtration and needs to be carefully evaluated during process modeling. Using fine and ultra-fine membrane filtration, and of course filtration with diatomaceous earth (DE) or polymeric filters can be cost effective with higher efficiencies and lower capital costs. The target protein can be separated by differential solubility by selectively tagging the protein, which induces aggregation or binding to specific media.

Purification Generally, the first step in purification is capture. This is normally accomplished through the use of specific chromatography resins such as ion exchange or affinity type resins. Resins are used in a variety of configurations such as the standard downflow system, radial chromatography, or streamline expanded-bed technology from Amersham Biosciences. The choice of capture system typically depends on the protein of interest and the cost of the resin.

Figure 4. Crude Protein Yield Based on Tobacco Biomass per Acre, and Expressions Levels Measured as % Total Soluble Protein (TSP)
Purification may employ several further chromatography steps including ion exchange, affinity, hydrophobic interaction, low-pressure reverse phase, or size exclusion. Each subsequent chromatography step is targeted for the removal of specific classes of contaminants such as host proteins, host compounds, host DNA, endotoxin, and environmental contaminants such as residual herbicides, pesticides, and bacterial and fungal toxins. Attention to interactions between target protein and plant phenolics is especially important during the purification process. A list of some of the contaminating molecules is shown in Table 3. Water, which is 80 to 90% of the wet weight, is not counted in this analysis of the dry solids.

Process ECONOMICS The manufacture of tobacco-produced proteins can be cost effective due to the low cost of field production and upstream processing, relative to the capital burden and operations-intensive processes used in traditional technologies such as mammalian cell culture. Various companies suggest that by eliminating expensive upstream equipment, the cost of therapeutic proteins made in transgenic systems may be an order of magnitude lower than the same proteins produced with traditional technologies. Others have reviewed process models, predicting that there may only be a savings of 10 to 15% over traditional cell culture systems. This is because upstream costs of traditional technologies are said to contribute less than one-half of the overall production costs, so an order of magnitude reduction in cost-of-goods using transgenic technology is not reasonable.18 However, the traditional model uses many standard unit operation criteria for both transgenic and cell culture systems that are not always applicable.

There are many ways to reduce the downstream costs associated with protein manufacturing. Often, when cost allocations are applied to upstream comparative construction and operations models, support or ancillary cost factors are not subtracted. Applying modular construction can reduce capital costs. Modular cleanroom components are pre-fabricated and are generally assembled within a low-cost shell structure. Although the modular components may contribute a higher cost per square foot to the cleanroom structure, the overall facility cost is generally less due to the simplified construction and readily available materials.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here